Eli Lilly Signs an Exclusive Worldwide License Agreement with Centrexion Therapeutics for its CNTX-0290

 Eli Lilly Signs an Exclusive Worldwide License Agreement with Centrexion Therapeutics for its CNTX-0290

Eli Lilly Signs an Exclusive Worldwide License Agreement with Centrexion Therapeutics for its CNTX-0290

Shots:

  • Centrexion to receive $47.5M upfront, up to $950M as development, regulatory & commercial milestones and royalties on sales of product. Lilly to get exclusive WW rights for CNTX-0290 & will co-promote CNTX-0290 with Centrexion in the US
  • The focus of the collaboration is to strengthen Lilly’s pain management portfolio and allow Centrexion to focus on new targets for chronic pain
  • Centrexion’s CNTX-0290 is a somatostatin receptor type 4 (SSTR4) agonist, is being evaluated in P-I as a non-opioid treatment for chronic pain

Click here to read full press release/ article | Ref: Eli Lilly | Image: Pinterest

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post